003060.KO Aprogen Pharmaceuticals Inc
- Market cap
- KRW 21.4B
- P/E
- -
- P/B
- 0.11x
- ROE
- -18.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 003060.KO undervalued?
Graham numberThe Graham number of Aprogen Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aprogen Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Aprogen Pharmaceuticals Inc yet.
Aprogen Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.
Full company profileAprogen Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aprogen Pharmaceuticals Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 44.1B | 46.1B | 45.4B | 50.9B | 53.3B | 56.5B | 65.2B | 87.4B | 67.4B | 73.2B | 89.4B |
| Gross Profit | 18.6B | 18.8B | 18.8B | 20.6B | 23.2B | 25.4B | 27.3B | -11.7B | -7.58B | -27.0B | -28.5B |
| Operating Income | -247M | -1.46B | -826M | -1.93B | -972M | -3.80B | -3.48B | -57.8B | -53.3B | -60.5B | -42.0B |
| EBITDA | - | -5.81B | 7.92B | 1.93B | 18.6B | 11.9B | 17.6B | -88.3B | -80.4B | -139B | 9.23B |
| Net Income | -3.92B | -16.4B | -1.22B | -8.31B | 11.3B | 8.10B | 12.6B | -118B | -105B | -170B | -35.7B |
| EPS | - | -129 | -7.54 | -30 | 28 | 20 | 2,458 | -180 | -7,966 | -12,925 | -2,712 |
| Balance Sheet | |||||||||||
| Total Assets | 129B | 158B | 217B | 365B | 615B | 615B | 684B | 589B | 591B | 587B | 548B |
| Total Liabilities | 50.6B | 80.4B | 66.6B | 17.6B | 17.0B | 17.4B | 174B | 221B | 212B | 309B | 281B |
| Shareholders' Equity | 80.4B | 77.9B | 151B | 246B | 505B | 508B | 427B | 369B | 378B | 208B | 194B |
| Cash & Short-term Investments | 26.2B | 23.8B | 21.6B | 30.3B | 64.8B | 35.1B | 23.6B | 10.1B | 12.3B | 24.4B | 22.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 450M | -8.93B | 1.33B | 714M | 8.09B | -6.23B | 25.7B | -33.7B | -31.0B | -38.2B | -31.6B |
| Capital Expenditure | 2.82B | 2.10B | 1.01B | 2.13B | 976M | 796M | 1.55B | 28.4B | 15.5B | 9.78B | 1.52B |
| Free Cash Flow | - | -11.6B | -913M | -1.71B | 6.67B | -7.67B | 24.2B | -62.0B | -46.4B | -48.0B | -33.1B |
| Ratios | |||||||||||
| ROE | -4.9% | -21.0% | -0.8% | -3.4% | 2.2% | 1.6% | 3.0% | -32.1% | -27.7% | -82.0% | -18.4% |
| ROA | -3.0% | -10.3% | -0.6% | -2.3% | 1.8% | 1.3% | 1.8% | -20.1% | -17.8% | -29.0% | -6.5% |
| Net Profit Margin | -8.9% | -35.5% | -2.7% | -16.3% | 21.1% | 14.3% | 19.4% | -135.4% | -155.8% | -232.6% | -40.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aprogen Pharmaceuticals Inc dividends
Aprogen Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 0.0667:1 on Apr 13, 2026.
Who owns Aprogen Pharmaceuticals Inc
- Insiders 72.85%
- Institutions 0.03%
- Public & others 27.13%
- Shares outstanding 16.3M
- Free float 6.18M
Aprogen Pharmaceuticals Inc company profile
- Company name
- Aprogen Pharmaceuticals Inc
- Ticker
- 003060.KO
- ISIN
- KR7003060001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 262
- Fiscal year end
- December
- Address
- 6, 31, Ogeum-ro 19-gil, Seoul, South Korea
- Phone
- 82 2 561 4011
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.
Aprogen Pharmaceuticals Inc management
2- Mr. Jeong-Chool KimChief Executive Officer
- Mr. Jung-Chul KimPresident